Allergy meds don’t work for most people

Several studies report that 66% of allergy sufferers are dissatisfied with their current allergy medications, reporting bothersome side effects, that they don’t work long or fast enough, and that they don’t treat the symptoms.

* Source

Currently available allergy medications can cause unpleasant side effects:

A large group of people should not be taking allergy medications: 

• Those with a chronic health condition such high blood pressure, heart disease, kidney or liver disease, glaucoma, or thyroid problems

• Pregnant or breastfeeding women

• Those who have contraindication with other medicines or supplements

• Those in certain jobs or operating machinery

Climate change

We believe the problem is only made worse by climate change, with longer and more intense allergy seasons causing prolonged suffering for more people.

* Source

Consumers seeking non-medicinal alternatives

Many of today’s consumers are actively seeking alternative therapies to live less toxic lives. For those seeking non-drug solutions, there has been no single natural remedy that can provide efficient symptom relief in one convenient treatment.

We are creating a new OTC category in allergy care

We believe we are the only company engineering a drug-free solution to curb allergy symptoms. The Fluo’s premarket clinical stage product is developed as an alternative to traditional allergy medications by using drug-free technology that tackles common allergy symptoms like congestion, runny nose, itchy nose and sneezing.

Fluo Labs is developing an OTC medical device that uses light therapy to deliver temporary drug-free relief of allergy symptoms.

Light therapy to reduce allergy symptoms?

Fluo Labs is developing an OTC medical device that uses light therapy to deliver temporary drug-free relief of allergy symptoms.

Our precisely engineered light structure is designed to target the inflammation caused by allergens and to temporarily reduce miserable nasal symptoms.

In 2017, allergy relief is a $24 billion global market and expected to grow beyond $40 billion by 2025 with a CAGR of 6.3%.

Currently, individuals suffering from moderate allergies spend an average of $650 per year on symptom relief, even though the majority (66%) report dissatisfaction with their current allergy medications.

Yet, there has been little incentive to innovate and develop better OTC allergy treatments in the past 30 years because existing medications are considered to “do a decent job”. 

Fluo Labs is bringing a novel and modern solution to this neglected space

In what we believe is another classic tale of disruption, we are developing an entirely new category in allergy care. It’s a complete departure from the conventional allergy relief protocols. 

Our premarket clinical device is being developed as an OTC consumer product that is a drug-free alternative to antihistamines and corticosteroids. 

Strategic partnership

We are thrilled to be partnering with a leading global life sciences company. The partnership champions Fluo Labs’ vision to bring its technology to a global stage. The partnership’s financial component will help Fluo Labs fulfill its mission to improve the quality of life for millions of allergy sufferers across the globe. The partner’s support and leadership in regulatory, marketing and commercialization matters will help Fluo Labs accelerate its plans to bring innovation to the fast-growing respiratory care category on a global scale. 

Under our agreement, we agreed to not disclose our partner’s name at this time as we work diligently to establish the next phases of our partnership.

Proof-of-concept studies, patents, and awards

In an IRB-sanctioned one-arm proof-of-concept study during the Fall ragweed season, subjects reported a 31% improvement in the subjects’ Total Nasal Symptom Score (TNSS) over baseline, which is the gold standard in nasal allergy tests. The results were significant, and promising as they were superior to what is typically found in studies for antihistamines.

* Source: Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Benninger M, Farrar JR, Blaiss M, Chipps B, Ferguson B, Krouse J, Marple B, Storms W, Kaliner M. Ann Allergy Asthma Immunol. 2010 Jan;104(1):13-29.

We recently conducted a series of in vitro tests to shed additional light on how our light therapy produces an effect in the body to alleviate nasal allergy symptoms. We learned in particular that certain proteins that help control inflammatory reactions responded immediately and favorably to our dosage of light. 

These preliminary results could support the argument that light therapy offers a broader and more efficient solution compared to conventional allergy medications and could  further make the case that it can act as a prophylaxis. We intend to undertake additional studies to further clarify the mechanism of action.

Fluo Labs has been granted two patents and has filed for two additional patents in January 2021 and a third in June 2021.

We also are seeking to complete product development, clinical evaluations, obtain a FDA De Novo grant and CE certification for a technology that could help allergy sufferers to reduce their allergy symptoms without having to use medication. We anticipate submitting a De Novo petition to the FDA for the Fluo device later in 2021.

Fluo Labs was a finalist at P&G Ventures 3rd Innovation Challenge. Finalists were selected on the basis of their potential to transform the lives of individuals and families. 

*Concept design only. Investigational device not currently available for sale.

Our fans can't wait!

* These testimonials may not be representative of the experience of other customers and are not a guarantee of future performance or success.

*Concept design only. Investigational device not currently available for sale.

The Fluo is seeking to improve wellness and quality of life of allergy sufferers and has designed a solution that acts as a natural, drug-free antihistamine by using light therapy. Non-medicinal alternatives are especially important in an era where consumers increasingly choose natural and clean remedies over drug-based medications. 

Fluo Labs is pioneering photobiomodulation, a form of light therapy, to reduce the symptoms of seasonal allergies.  

Photobiomodulation is commonly used in the medical community to relieve pain, reduce inflammation, heal wounds and regenerate tissue. In the case of nasal allergies, we are finding that photobiomodulation triggers specific biochemical interactions that serve as a natural dampener of the body’s over-response to allergens. 

Light therapy can reduce the symptoms of nasal allergies like sneezing, congestion, itchy nose and runny nose.

The Fluo device is designed to be easy and fast to use with a treatment that takes less than 30 seconds. Here’s how our prototype currently works:

We are pre-revenue, and no revenue will be generated prior to obtaining regulatory approval. If approved, we plan to introduce the Fluo as an over-the-counter repeat-purchase product with a  direct-to-consumer approach.

We are also launching a community marketing initiative under the Seize the Sneeze ™  banner to capture consumer insights on their personal experience with allergies. 

In the longer term, we plan to open new channel partnerships in an  omnichannel strategy to cross into traditional retail. 

We will be making it our duty to provide relief to the millions of people who are needlessly suffering from allergies. We hope to substantially improve their quality of life with a “clean” drug-free solution that will quickly get them back to functioning at their best.

It is our ambition to see Fluo Labs’ therapy become the standard for treating the symptoms of seasonal allergies everywhere.

We’re proud of our team of highly specialized scientists, engineers and professionals who have already committed years of research into developing this solution. 

Our recognized experts have practiced in the fields of light therapeutics, allergy medication development, digital commerce, growth marketing, fulfillment and distribution. They bring preclinical and clinical development, and global industry expertise to the development of our innovative premarket clinical allergy relief device. These experts have extensive experience on how to design and conduct clinical studies to clinically demonstrate and satisfy the high standards of the FDA.

The global allergy treatment market represents a huge market opportunity, predicted to hit $40 billion in 2025. 

Seasonal allergies aren’t going away, and we are tired of seeing the massive physical, mental, economic, and social struggle of so many allergy sufferers around the world. 

We see it as our duty to provide allergy sufferers with a natural, effective treatment for their symptoms, and we need your help to make it happen.

Since seasonal allergies impact so many people around the world, we feel that the equity crowdfunding process is an opportunity to build a greater community of investors and consumers committed to our groundbreaking product. 

Are you ready to help millions of people seize the sneeze?

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY.  THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS.  INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.